Ep. 33 How Lytix Biopharma Reimagined Host-Defense Peptides as Oncolytic Molecules for Immunotherapy

About this episode

Øystein Rekdal discusses Lytix Biopharma's innovative approach to cancer immunotherapy using host-defense peptides.

In this episode of Spark Time!, we speak with Øystein Rekdal, co-founder and CEO of Lytix Biopharma, about how the company reimagined host-defense peptides as a new class of oncolytic molecules for cancer immunotherapy. Øystein shares the full arc of Lytix's development, from an academic discovery in Norway to a clinical-stage platform built around locally administered oncolytic molecules designed to activate the immune system where standard treatments fall short. We explore how Lytix isolated and engineered naturally occurring peptides into drug candidates with clinical momentum, and why this approach differs fundamentally from both traditional cytotoxic agents and oncolytic viruses. The conversation dives into how Lytix's lead program induces immunogenic cell death, exposes tumor antigens, and initiates a broad immune response that extends beyond the treated lesion. We also discuss the company's strategic focus on combination and neo-adjuvant settings, its rationale for intratumoral delivery, and how this platform is positioned to address non-responsive solid tumors. A thoughtful discussion for biotech leaders, investors, and partners interested in differentiated immunotherapy…

People in this episode

Guest: Øystein Rekdal

Topics covered

• immunotherapy
• cancer treatment
• biotechnology
• host-defense peptides
• oncolytic molecules
• clinical development

Keywords

• Lytix Biopharma
• immunogenic cell death
• tumor antigens
• intratumoral delivery
• solid tumors
• biotech
• cancer immunotherapy

Mentioned in this episode

Organizations: Lytix Biopharma

Places: Norway